Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

HANOVER, Germany, Sept. 17, 2024 /PRNewswire/ -- At IAA Transportation 2024, Contemporary Amperex Technology Co., Limited (CATL), the global leader in new energy technology innovations launched its groundbreaking TECTRANS battery system, revolutionizing the commercial transportation sector.

TECTRANS represents a quantum leap in battery technology for commercial vehicles, offering unprecedented energy density, faster charging capabilities, and enhanced durability. This innovative system is poised to transform the electric commercial vehicle landscape, providing fleet operators with extended range, reduced downtime, optimized cost-effectiveness, and improved overall efficiency.

Unmatched Energy Density, Fast Charge and Lifespan: The Future of Electric Trucks and Buses

For heavy-duty trucks, CATL introduces two groundbreaking products: the TECTRANS - T Superfast Charging Edition and the TECTRANS - T Long Life Edition. The Superfast Charging Edition features a remarkable 4C peak charging rate, allowing for a 70% charge in just 15 minutes. This rapid charging capability minimizes vehicle downtime and maximizes operational efficiency for fleet operators.

The TECTRANS - T Long Life Edition sets a new industry benchmark with an exceptional lifespan of up to 15 years or 2.8 million kilometers. This durability is crucial for the demanding nature of commercial operations, particularly in high-frequency, energy-intensive scenarios such as port operations and bulk transportation.

Both truck editions offer impressive driving ranges of up to 500 kilometers, catering to various operational needs from short-haul port deliveries to long-distance transportation.

The CATL TECTRANS - Bus Edition is a cutting-edge battery solution for long-distance passenger transport, featuring an industry-leading energy density of 175Wh/kg, the highest for LFP chemistry used in bus applications. Its compact design offers long-range capabilities and low energy consumption, enhancing vehicle layout flexibility. The advanced thermal management system maintains optimal performance across various climates, reducing internal temperature disparity by 50% and ensuring longevity even in extreme conditions.

In July of this year, CATL launched its light truck solutions in China, expanding the TECTRANS portfolio to cover a wider range of commercial vehicle applications. These solutions offer enhanced energy density and fast-charging capabilities, addressing the unique needs of urban delivery and last-mile logistics.

Akin Li, Executive President of CATL Overseas Business, highlighted the exceptional reliability of CATL batteries in various challenging environments: "Our batteries have proven their reliability and performance in extreme conditions, from operating in temperatures above 45°C in Qatar and Dubai to withstanding -35°C in Arctic countries like Norway and Sweden. The launch of the Tectrans and the product lines demonstrates our unwavering commitment to driving energy transition through continuous innovation."

Advanced technologies Drive the Electricfication of Commercial Vehicles

The main concerns facing the commercial vehicle industry in its shift towards electrification are recharging time, cost and range. Tectrans is set to create value more commercial fleets by incorporating several cutting-edge technologies that contribute to its superior performance in high energy density, fast charging capabilities, and extended cycle life.

"As the global industry leader, CATL is committed to pushing the boundaries of what's possible in electric transportation," said Akin Li, Executive President of CATL Overseas Business. "TECTRANS is the culmination of our extensive R&D efforts and represents a significant step forward in commercial vehicle electrification. We're excited to showcase this technology at IAA Transportation and demonstrate how it will accelerate the global transition to sustainable transport."

Sustainable Electrification of Road Transportation

At this year's IAA Transportation, CATL shows a wide range of cells and packs tailored for different application scenarios, including trucks, buses, ships, and construction machinery.

While providing safe, reliable and cost-effective products and services to customers to support global climate ambition, CATL is also committed to sustainable practices throughout the battery lifecycle. It aspires to reach net zero in battery manufacturing operations by 2025 and across the battery supply chain by 2035. These milestones will help reduce more than 40% of emissions during the lifespan of an electric vehicle. So far CATL has achieved carbon neutrality in nine factories.

The company has established seven major recycling industry hubs globally, with its subsidiary Brunp Recycling achieving a recovery rate of over 99.6% for nickel, cobalt and manganese, and 91% for lithium. With a capacity to process 270,000 tons of used batteries annually, CATL is paving the way for batteries made entirely from recycled materials, significantly reducing the need for new mining operations.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

Breakthrough in the electrification of commercial vehicles: CATL Unveils Revolutionary TECTRANS Battery System

SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a Phase 1 study". The update data from ABSK-011-101 study showed a tolerable safety profile and promising anti-tumor activity of Irpagratinib monotherapy in aHCC. Of note, in aHCC patients who were pretreated with both immune checkpoint inhibitor (ICI) and Tyrosine Kinase Inhibitor (TKI)—a population with high unmet need in the current treatment paradigm—the observed ORR and DCR was 44.8% and 79.3%, respectively, with a median duration of response (mDoR) of 7.4 months and median progression free survival (mPFS) of 5.5 months.

The poster, #983P, was presented at the Hepatocellular Carcinoma poster session on Sunday, September 16, 2024. The Best Poster Award was given at the conclusion of the Sunday Poster Session, with only one recipient being honored in HCC poster session.

As of September 5, 2024, 122 patients have been enrolled, including 74 in the BID cohort with doses consisting of 160mg BID, 220mg BID, and 300mg BID. 5.4% of patients were BCLC Stage B, and 89.2% BCLC Stage C, 64.9% had a Child-Pugh (CP) Score of 5, 27% CP Score of 6, and 6.8% CP Score of 7. 64.9% of patients received multiple lines of prior therapy, 85.1% of patients had previously been treated with ICIs, and 75.7% of patients had previously been treated with both ICIs and mTKIs.

The efficacy data show that forty pre-treated HCC patients with FGF19 overexpression were treated with irpagratinib 220 mg BID. Among the 38 evaluable patients, the response rate was 36.8% (14/38), and the disease control rate (DCR) was 78.9% (30/38). The response rate from the subset of patients who had previously received ICI and mTKI therapy was 44.8% (13/29). The longest observed DoR was 16.4 months and the mDoR was 7.4 months. DCR was 79.3% (23/29). mPFS was 5.5 months.

Safety data show one dose-limiting toxicity (DLT) was observed in the 300 mg BID cohort. The most common treatment-related adverse effects (TRAEs, >20%) were ALT elevation, diarrhea, AST elevation, hyperphosphatemia, bilirubin elevation, alkaline phosphatase elevation, platelet decrease, and total bile acid elevation. Grade 3-4 treatment-related adverse events (>5%) included AST elevation, ALT elevation, and diarrhea. No grade 5 adverse events occurred.

HCC is the main type of liver cancer, accounting for 85% to 90% of primary liver cancers.  HCC is highly malignant, about 30% of which have abnormally high FGFR4 expression and a poor prognosis, and the existing treatment methods still cannot meet the long-term survival benefits.  Currently, there is no approved standard of care for HCC patients who have progressed from first-line ICI-based therapies. The FGF19/FGFR4 signaling axis could be a novel therapeutic target for HCC. ABSK-011, a potent FGFR4 inhibitor, demonstrated a tolerable safety profile and promising anti-tumor activity as a single agent. Notably, the irpagratinib 220mg BID regimen exhibited a 44.8% ORR, 7.4 months mDoR and 5.5 months mPFS in heavily pre-treated HCC patients who had received both ICI and mTKI therapy, supporting further late-stage development of irpagratinib in such populations with substantial unmet medical need.

In addition, the design of the phase II study of pimicotinib in combination with chemotherapy and with/without toripalimab as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC) has been presented.

About Irpagratinib (ABSK011)

Irpagratinib is a highly selective FGFR4 small molecule inhibitor intended for the treatment of advanced solid tumors that present with abnormalities in the FGF19/FGFR4 signaling pathway (e.g., ligand FGF19 amplification/overexpression, FGFR4 mutation/amplification/fusion), including advanced HCC, cholangiocarcinoma, breast cancer, among others. The FGFR4 signaling pathway is a recognized and promising target for treating HCC. Clinical data with irpagratinib have demonstrated improved potency and anti-tumor efficacy, among other favorable therapeutic properties, compared to competitors.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to the discovery and development of innovative medicines that treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology. Please visit www.abbisko.com for more information.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC